| Autor: |
Petrikis P; Department of Psychiatry, University of Ioannina School of Medicine, Ioannina, Greece., Tigas S; Department of Endocrinology, University of Ioannina School of Medicine, Ioannina, Greece., Tzallas AT; Department of Informatics and Telecommunications, School of Informatics and Telecommunications, University of Ioannina, Arta, Greece., Ntritsos G; Department of Informatics and Telecommunications, School of Informatics and Telecommunications, University of Ioannina, Arta, Greece.; Department of Hygiene and Epidemiology, University of Ioannina, School of Medicine, Ioannina, Greece., Sioka C; Department of Nuclear Medicine, University of Ioannina, School of Medicine, Ioannina, Greece., Georgiou G; Department of Psychiatry, University of Ioannina School of Medicine, Ioannina,Greece., Karampas A; Department of Psychiatry, University of Ioannina School of Medicine, Ioannina,Greece., Skapinakis P; Department of Psychiatry, University of Ioannina School of Medicine, Ioannina,Greece., Mantas C; Department of Psychiatry, University of Ioannina School of Medicine, Ioannina,Greece., Hyphantis T; Department of Psychiatry, University of Ioannina School of Medicine, Ioannina,Greece. |
| Abstrakt: |
Diabetes and dyslipidemia are common in patients with psychosis and may be related to adverse effects of antipsychotic medications. Metabolic disturbances in first-episode patients with psychosis are common, even prior to any antipsychotic treatment, and antipsychotic medications are implicated in the development of metabolic syndrome, at least in the long run. We therefore aimed to follow a group of drug-naïve, first-episode patients with psychosis at different time points (baseline, six months, and 36 months after the initiation of antipsychotic treatment) in order to evaluate the progression of metabolic abnormalities after antipsychotic therapy and the time-course of their onset. We assessed glucose and lipid metabolism during the fasted state in 54 drug-naïve patients with first-episode psychosis (FEP) before the initiation of any antipsychotic treatment and compared them with matched controls. The same parameters were assessed in the patient group (n=54) after six months of antipsychotic treatment and in a subgroup of patients (n=39) after three years of continuous and stable treatment in comparison to baseline. Measurements were obtained for fasting serum concentrations of total cholesterol, triglycerides, high density lipoprotein (HDL), glucose, insulin, connecting peptide (C-peptide), homeostatic model assessment index (HOMA-IR), glycated hemoglobin (HbA1c) and body mass index (BMI). Insulin, C-peptide, triglyceride levels, and HOMA-IR index were significantly higher compared to controls. Total cholesterol, triglyceride levels and BMI, increased significantly in the patient group after six months of antipsychotic treatment. After three years of continuous antipsychotic treatment, we found statistically significant increases in fasting glucose, insulin, total cholesterol, triglyceride levels, HbA1c, HOMA-IR index, and BMI compared to baseline. In conclusion, FEP patients developed significant increases in BMI and serum lipid levels as soon as six months after antipsychotic treatment. These metabolic abnormalities persisted following 36 months of treatment and in addition, increases in fasting glucose, insulin, HbA1c and HOMA-IR were observed compared to baseline. |
